Correction to: European headache federation guideline on the use of monoclonal antibodies acting on...
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
About this item
Full title
Author / Creator
Publisher
Milan: Springer Milan
Journal title
Language
English
Formats
Publication information
Publisher
Milan: Springer Milan
Subjects
More information
Scope and Contents
Contents
Following publication of the original article [1], the authors notified us of some misreported data due to the publication of the EVOLVE-2 trial (Cephalalgia. 2018;38:1442–1454), which substantially changed the level of evidence of galcanezumab for the prevention of episodic migraine. All changes are marked in bold and with red in Figure 1 and Figu...
Alternative Titles
Full title
Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_55c34ad2b80d49b6aa017cb2c0459e68
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_55c34ad2b80d49b6aa017cb2c0459e68
Other Identifiers
ISSN
1129-2369
E-ISSN
1129-2377
DOI
10.1186/s10194-019-0972-5
